Stamford Therapeutics Consortium

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Obesity8 trials
• Type 2 diabetes5 trials
• Lyme disease3 trials
• Rheumatoid arthritis2 trials
• Coeliac disease1 trial
• Psoriasis1 trial

Phase

• Phase 28 trials
• Phase 36 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Completed7 trials
• Recruiting4 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company10 trials
• Pfizer2 trials
• Bristol-Myers Squibb1 trial
• Chugai Pharmaceutical1 trial
• ModernaTX, Inc.1 trial
• and 1 more

Running trials

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Eli Lilly and Company· Source

  Contact: David Radin (principal investigator)

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Eli Lilly and Company· Source

  Contact: David Radin (principal investigator)

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Eli Lilly and Company· Source

  Contact: David Radin (principal investigator)

• Recruiting

  Study of DONQ52 in Active Celiac Disease

  NCT07239336· Phase 2· Chugai Pharmaceutical· Source

• Recruiting

  A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

  NCT06672939· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  NCT06672549· Phase 3· Eli Lilly and Company· Source

  Contact: David Radin (principal investigator)

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Eli Lilly and Company· Source

  Contact: David Radin (principal investigator)

• Active, not recruiting

  Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

  NCT04539964· Phase 3· SetPoint Medical Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity4 recruiting
• Type 2 diabetes3 recruiting
• Coeliac disease1 recruiting

Closed trials

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

  NCT05975099· Phase 1/2· ModernaTX, Inc.· Source

• Completed

  Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

  NCT05634811· Phase 3· Pfizer· Source

• Completed

  Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

  NCT04801420· Phase 2· Pfizer· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source